Program-Level Neoadjuvant Chemotherapy Use and 10-Year Survival in Advanced Ovarian Cancer - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Neoadjuvant Chemotherapy Strategies and a Decade of Survival Outcomes in Advanced Ovarian Cancer

  • By

  • Alex E. R. Powers

  • Gretchen Davis

  • Deshae Jenkins

  • Alicia Youssef

  • William Manning

  • Jason D. Wright

  • Nancy L. Keating

  • Amy Bregar

  • Alejandro Rauh-Hain

  • Alexander Melamed

  • September 17, 2026

Share

Clinical Report: Neoadjuvant Chemotherapy Strategies and a Decade of Survival Outcomes in Advanced Ovarian Cancer

Overview

This study evaluates the long-term survival outcomes associated with neoadjuvant chemotherapy (NACT) in advanced ovarian cancer. It finds no significant association between NACT adoption and 10-year survival rates.

Background

The management of advanced-stage epithelial ovarian cancer typically involves a combination of cytoreductive surgery and chemotherapy. The sequence of these treatments, particularly the role of NACT versus primary debulking surgery, remains a subject of debate among clinicians, impacting treatment decisions and patient outcomes.

Data Highlights

Program Type10-Year Survival Probability10-Year Restricted Mean Survival Time (months)
Low-Use Programs15.1% to 19.1%45.7 to 51.4
High-Use Programs15.6% to 20.0%47.1 to 53.5

Key Findings

  • NACT use increased from 21.5% to 42.8% in high-use programs.
  • 10-year survival probability improved similarly in both low-use and high-use programs.
  • No significant association was found between NACT adoption and long-term survival outcomes.
  • Standardized 10-year survival probability increased by 4.0 percentage points in low-use and 4.3 percentage points in high-use programs.
  • 10-year restricted mean survival time rose in both program types, indicating comparable improvements.

Clinical Implications

The findings indicate that NACT does not appear to confer a long-term survival advantage over traditional treatment approaches.

Conclusion

The study highlights the need for ongoing evaluation of treatment strategies in advanced ovarian cancer regarding the long-term impact of NACT on survival outcomes.

Related Resources & Content

  1. ASCO Updates Guidelines on Neoadjuvant Chemotherapy in Advanced Ovarian Cancer, The ASCO Post, 2025 -- ASCO Updates Guidelines on Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
  2. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer, New England Journal of Medicine, 2010 -- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
  3. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer Guideline Summary, Guideline Central -- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer Guideline Summary
  4. The ASCO Post — What We Know and What We Need to Know About Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
  5. The ASCO Post — Intraperitoneal Chemotherapy Gives Ovarian Cancer Patients Better Chance of Survival
  6. The ASCO Post — Expert Point of View: Kunle Odunsi, MD, PhD and Lilian T. Gien, MD, MSc
  7. What We Know and What We Need to Know About Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
  8. Intraperitoneal Chemotherapy Gives Ovarian Cancer Patients Better Chance of Survival
  9. ASCO Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer Guideline Summary - Guideline Central
  10. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer | New England Journal of Medicine
  11. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline - PMC

Original Source(s)

Related Content